Cargando…

Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis

BACKGROUND: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs). METHODS: A total of 60 SLE patients, 70 RA patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Peng, Ni, Jing, Chu, Ya-Ya, Chen, Qing-Qing, Wu, Guo-Cui, Fang, Yang, Chen, Cong, Zhang, Ruo-Di, Jiang, Ling-Qiong, Zhao, Yan, Fang, Xi, He, Jun, Wang, De-Guang, Wang, Gui-Hong, Pan, Hai-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Masson SAS. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040458/
https://www.ncbi.nlm.nih.gov/pubmed/35486976
http://dx.doi.org/10.1016/j.biopha.2022.112997
_version_ 1784694340744904704
author Wang, Peng
Ni, Jing
Chu, Ya-Ya
Chen, Qing-Qing
Wu, Guo-Cui
Fang, Yang
Chen, Cong
Zhang, Ruo-Di
Jiang, Ling-Qiong
Zhao, Yan
Fang, Xi
He, Jun
Wang, De-Guang
Wang, Gui-Hong
Pan, Hai-Feng
author_facet Wang, Peng
Ni, Jing
Chu, Ya-Ya
Chen, Qing-Qing
Wu, Guo-Cui
Fang, Yang
Chen, Cong
Zhang, Ruo-Di
Jiang, Ling-Qiong
Zhao, Yan
Fang, Xi
He, Jun
Wang, De-Guang
Wang, Gui-Hong
Pan, Hai-Feng
author_sort Wang, Peng
collection PubMed
description BACKGROUND: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs). METHODS: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA). RESULTS: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2. CONCLUSION: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19.
format Online
Article
Text
id pubmed-9040458
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Masson SAS.
record_format MEDLINE/PubMed
spelling pubmed-90404582022-04-26 Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis Wang, Peng Ni, Jing Chu, Ya-Ya Chen, Qing-Qing Wu, Guo-Cui Fang, Yang Chen, Cong Zhang, Ruo-Di Jiang, Ling-Qiong Zhao, Yan Fang, Xi He, Jun Wang, De-Guang Wang, Gui-Hong Pan, Hai-Feng Biomed Pharmacother Article BACKGROUND: This study aimed to investigate the seroreactivity of Coronavirus disease 2019 (COVID-19) vaccination and its adverse events among systemic lupus erythematosus (SLE) patients, rheumatoid arthritis (RA) patients, and healthy controls (HCs). METHODS: A total of 60 SLE patients, 70 RA patients and 35 HCs, who received a complete inactivated COVID-19 vaccine (Vero cells) regimen, were recruited in the current study. Serum IgG and IgM antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) were determined by using chemiluminescent microparticle immunoassay (CMIA). RESULTS: There were no significant differences regarding the seroprevalences of IgG and IgM antibodies against SARS-CoV-2, and the self-reported vaccination-related adverse events among SLE patients, RA patients and HCs. The inactivated COVID-19 vaccines appeared to be well-tolerated and moderately immunogenic. In addition, case-only analysis indicated that in SLE patients, the disease manifestation of rash and anti-SSA autoantibody were associated with seroprevalence of IgG antibody against SARS-CoV-2, whereas the uses of ciclosporin and leflunomide had influence on the seroprevalence of IgM antibody against SARS-CoV-2. In RA patients, rheumatoid factor (RF) appeared to be associated with the seroprevalence of IgG antibody against SARS-CoV-2. CONCLUSION: Our study reveals that the seroprevalences of IgG and IgM antibodies against SARS-CoV-2 and vaccination-related adverse effects are similar among SLE, RA and HCs, suggesting that COVID-19 vaccine is safe and effective for SLE and RA patients to prevent from the pandemic of COVID-19. The Author(s). Published by Elsevier Masson SAS. 2022-06 2022-04-26 /pmc/articles/PMC9040458/ /pubmed/35486976 http://dx.doi.org/10.1016/j.biopha.2022.112997 Text en © 2022 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Wang, Peng
Ni, Jing
Chu, Ya-Ya
Chen, Qing-Qing
Wu, Guo-Cui
Fang, Yang
Chen, Cong
Zhang, Ruo-Di
Jiang, Ling-Qiong
Zhao, Yan
Fang, Xi
He, Jun
Wang, De-Guang
Wang, Gui-Hong
Pan, Hai-Feng
Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
title Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
title_full Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
title_fullStr Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
title_full_unstemmed Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
title_short Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
title_sort seroprevalence of sars-cov-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040458/
https://www.ncbi.nlm.nih.gov/pubmed/35486976
http://dx.doi.org/10.1016/j.biopha.2022.112997
work_keys_str_mv AT wangpeng seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT nijing seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT chuyaya seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT chenqingqing seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT wuguocui seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT fangyang seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT chencong seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT zhangruodi seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT jianglingqiong seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT zhaoyan seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT fangxi seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT hejun seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT wangdeguang seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT wangguihong seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis
AT panhaifeng seroprevalenceofsarscov2specificantibodiesandvaccinationrelatedadverseeventsinsystemiclupuserythematosusandrheumatoidarthritis